Back to search results
NCT06925477

Direct vs. Conventional SLT in Open-Angle Glaucoma: A RCT

Enrolling by Invitation
NAAges 18+InterventionalTreatment
Medical University of South Carolina
~51 participants
Updated 2025-10-02 on ClinicalTrials.gov
What's tested:DSLT treatment for Open-Angle GlaucomaSLT treatment for Open-Angle Glaucoma

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Primary Endpoint
Measured over 6 months

Conditions

GLAUCOMA 1, OPEN ANGLE, D (Disorder)

Explore related trials

Ocular HypertensionOpen Angle Glaucoma

Where it's being run

1 sites across 1 states
South Carolina1

Study leadership

  • Jella An, MD, MBA · PRINCIPAL_INVESTIGATOR · Medical University of South Carolina

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥18 years.
Diagnosed with OAG (including exfoliative/pigmentary glaucoma) or OHT.
Gonioscopically visible scleral spur for 360 degrees.
Ability to provide informed consent.
In good health, without prior laser trabeculoplasty, with decision to treat made by an ophthalmologist on the basis of risk profile, patient preference, or both.
Each eye with one of the following qualifying diagnoses (diagnoses may differ between eyes):
High-risk ocular hypertension (OHT): IOP \> 21 mmHg without glaucomatous optic neuropathy (excavation, diffuse or focal thinning or notching of the neuroretinal rim, visible nerve fiber layer defects, or asymmetry of the vertical cup-to-disc ratio of \>0.2 between eyes) \[enrollment of trial participants with High-risk OHT will be capped at 25% of total enrollment\]
Mild primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation \>-6.0 dB with no points in the central 5° \<15 dB
Moderate primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation -6.0 dB to \>-12 dB and no more than 1 central 5° point \<15 dB

Exclusion

Advanced POAG in either eye
Glaucoma other than OAG (including pigmentary and pseudoexfoliation glaucoma) in either eye
Mean IOP \> 35 mmHg at either the screening or baseline visit in either eye
Narrow or closed angle (Shaffer Grade 0, 1, or 2) in either eye
Contraindications to SLT, brimonidine, apraclonidine, or any other study intervention
Any corneal pathology that would preclude accurate assessment of IOP by Goldmann tonometry in either eye
Any intraocular surgical procedure within the past 6 months in either eye
Inability to attend all scheduled study visits
Pregnancy or plan to become pregnant in the next 1 year
Any prior laser trabeculoplasty, including ALT, MLT and SLT.

What this trial measures

  • Primary Endpoint6 months

    Measuring the difference in the average IOP measurement reduction from the patient's baseline at 6 months between the DSLT and the SLT groups.